Avenue Therapeutics Inc expected to post a loss of 26 cents a share - Earnings Preview

Avenue Therapeutics

30/10/2023 18:33

* Avenue Therapeutics Inc  ATXI.OQ   ATXI.O  is expected
to report
results
    * 
    * ​Refinitiv's mean analyst estimate for Avenue Therapeutics
Inc
is for a loss of 26 cents per share. 
    * The one available analyst rating on the shares is "buy".  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Avenue
Therapeutics Inc is $32​, above​ its last closing price
of $0.38. ​​​

This summary was machine generated October 30 at 18:32 GMT.  All
figures in US dollars  unless otherwise stated